132044Omnigen: Novel Stem Cell Treatment for Acute Ocular Surface TraumaClosedFeasibility StudiesInnovate UKThere are millions of corneal trauma cases globally each year. Without effective treatment, ocular surface trauma can progress to long term complication and corneal blindness. Amniotic membrane has been used in ophthalmic surgery to treat disease and damage to the surface of the eye. Unfortunately clinical usage of amnion has been severely limited as it is not readily available on demand at the hospital, especially in the treatment of an emergency eye injury case. NuVision has noted this restriction and devised OmnigenTM, an immediately accessible, dry amnion-derived product that will have a much greater utility and uptake, making amnion a realistic proposition for adoption by ophthalmic surgeons into emergency medicine